Pfizer Inc. with ticker code (PFE) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $50.00 and $26.00 suggesting an average analyst share price target price of $32.09. (at the time of writing). Given that the stocks previous close was at $27.70 and the analysts are correct then there would likely be a percentage uptick in value of 15.8%. There is a 50 day moving average of $27.56 and the 200 day MA is $31.90. The market cap for the company is 156.63B. The stock price for the company is currently $27.66 USD
The potential market cap would be $181,448,498,443 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 74.76, revenue per share of $10.37 and a 1.55% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
